# Seres Therapeutics, Inc.: financial statements, quarterly

MCRB · Nasdaq · CIK 1609809 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mcrb.md) · [Financials](/companies/mcrb/financials.md) · [Filings](/companies/mcrb/filings.md) · [Insiders](/companies/mcrb/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mcrb/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.3](/filings/0000950170-23-057805.md) | [(126) d](/filings/0001193125-26-103276.md) | [0.0](/filings/0000950170-24-055159.md) | [0.0](/filings/0000950170-24-095821.md) | [0.0](/filings/0001193125-25-266011.md) | [0.0 d](/filings/0001193125-26-103276.md) | [0.0](/filings/0001193125-26-205434.md) | [0.0](/filings/0001193125-26-334174.md) | [0.4](/filings/0001193125-25-266011.md) | [0.4 d](/filings/0001193125-26-103276.md) | [0.4](/filings/0001193125-26-205434.md) | [0.7](/filings/0001193125-26-334174.md) |
| Research and development | $m | [25.2](/filings/0000950170-24-126018.md) | [23.0 d](/filings/0001193125-26-103276.md) | [19.5](/filings/0000950170-25-065173.md) | [15.8](/filings/0000950170-25-103611.md) | [16.5](/filings/0001193125-25-266011.md) | [12.8 d](/filings/0001193125-26-103276.md) | [11.8](/filings/0001193125-26-205434.md) | [12.9](/filings/0001193125-26-334174.md) | [12.6](/filings/0001193125-25-266011.md) | [11.7 d](/filings/0001193125-26-103276.md) | [13.2](/filings/0001193125-26-205434.md) | [9.1](/filings/0001193125-26-334174.md) |
| Operating income | $m | [(44.6)](/filings/0000950170-24-126018.md) | [(37.0) d](/filings/0001193125-26-103276.md) | [(34.4)](/filings/0000950170-25-065173.md) | [(28.9)](/filings/0000950170-25-103611.md) | [(29.2)](/filings/0001193125-25-266011.md) | [(28.8) d](/filings/0001193125-26-103276.md) | [(27.2)](/filings/0001193125-26-205434.md) | [(24.9)](/filings/0001193125-26-334174.md) | [(22.5)](/filings/0001193125-25-266011.md) | [(19.4) d](/filings/0001193125-26-103276.md) | [(20.9)](/filings/0001193125-26-205434.md) | [(21.3)](/filings/0001193125-26-334174.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-126018.md) | [0.0 d](/filings/0001193125-26-103276.md) | [0.0](/filings/0000950170-25-065173.md) | [0.0](/filings/0000950170-25-103611.md) | [0.0](/filings/0001193125-25-266011.md) | [0.0 d](/filings/0001193125-26-103276.md) | [0.0](/filings/0001193125-26-205434.md) | [0.0](/filings/0001193125-26-334174.md) | [0.0](/filings/0001193125-25-266011.md) | [0.0 d](/filings/0001193125-26-103276.md) | [0.0](/filings/0001193125-26-205434.md) | [0.0](/filings/0001193125-26-334174.md) |
| Net income | $m | [(47.9)](/filings/0000950170-24-126018.md) | [(41.2) d](/filings/0001193125-26-103276.md) | [(40.1)](/filings/0001193125-25-266011.md) | [(32.9)](/filings/0001193125-25-266011.md) | [88.8](/filings/0001193125-25-266011.md) | [(15.6) d](/filings/0001193125-26-103276.md) | [32.7](/filings/0001193125-26-334174.md) | [(19.9)](/filings/0001193125-26-334174.md) | [8.2](/filings/0001193125-25-266011.md) | [(15.3) d](/filings/0001193125-26-103276.md) | [(19.9)](/filings/0001193125-26-334174.md) | [4.6](/filings/0001193125-26-334174.md) |
| Diluted EPS | $ per share | [(0.37)](/filings/0000950170-24-126018.md) | not reported | [(5.49)](/filings/0000950170-25-065173.md) | [(4.34)](/filings/0000950170-25-103611.md) | [11.63](/filings/0001193125-25-266011.md) | not reported | [3.75](/filings/0001193125-26-205434.md) | [(2.27)](/filings/0001193125-26-334174.md) | [0.94](/filings/0001193125-25-266011.md) | not reported | [(2.08)](/filings/0001193125-26-205434.md) | [0.47](/filings/0001193125-26-334174.md) |
| Basic EPS | $ per share | [(0.37)](/filings/0000950170-24-126018.md) | not reported | [(5.49)](/filings/0000950170-25-065173.md) | [(4.34)](/filings/0000950170-25-103611.md) | [11.63](/filings/0001193125-25-266011.md) | not reported | [3.76](/filings/0001193125-26-205434.md) | [(2.27)](/filings/0001193125-26-334174.md) | [0.94](/filings/0001193125-25-266011.md) | not reported | [(2.08)](/filings/0001193125-26-205434.md) | [0.47](/filings/0001193125-26-334174.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [170](/filings/0000950170-23-057805.md) | [128](/filings/0000950170-25-038427.md) | [111](/filings/0000950170-24-055159.md) | [71.2](/filings/0000950170-24-095821.md) | [66.8](/filings/0000950170-24-126018.md) | [30.8](/filings/0001193125-26-103276.md) | [58.8](/filings/0000950170-25-065173.md) | [45.4](/filings/0000950170-25-103611.md) | [47.6](/filings/0001193125-25-266011.md) | [45.8](/filings/0001193125-26-334174.md) | [29.8](/filings/0001193125-26-205434.md) | [15.6](/filings/0001193125-26-334174.md) |
| Current assets | $m | [214](/filings/0000950170-23-057805.md) | [175](/filings/0000950170-25-038427.md) | [165](/filings/0000950170-24-055159.md) | [149](/filings/0000950170-24-095821.md) | [72.9](/filings/0000950170-24-126018.md) | [38.7](/filings/0001193125-26-103276.md) | [66.1](/filings/0000950170-25-065173.md) | [48.7](/filings/0000950170-25-103611.md) | [51.5](/filings/0001193125-25-266011.md) | [49.4](/filings/0001193125-26-334174.md) | [31.8](/filings/0001193125-26-205434.md) | [42.3](/filings/0001193125-26-334174.md) |
| Total assets | $m | [368](/filings/0000950170-23-057805.md) | [359](/filings/0000950170-25-038427.md) | [341](/filings/0000950170-24-055159.md) | [322](/filings/0000950170-24-095821.md) | [179](/filings/0000950170-24-126018.md) | [140](/filings/0001193125-26-103276.md) | [164](/filings/0000950170-25-065173.md) | [144](/filings/0000950170-25-103611.md) | [143](/filings/0001193125-25-266011.md) | [138](/filings/0001193125-26-334174.md) | [118](/filings/0001193125-26-205434.md) | [102](/filings/0001193125-26-334174.md) |
| Current liabilities | $m | [79.2](/filings/0000950170-23-057805.md) | [98.7](/filings/0000950170-25-038427.md) | [98.5](/filings/0000950170-24-055159.md) | [108](/filings/0000950170-24-095821.md) | [64.8](/filings/0000950170-24-126018.md) | [41.2](/filings/0001193125-26-103276.md) | [31.3](/filings/0000950170-25-065173.md) | [30.9](/filings/0000950170-25-103611.md) | [22.4](/filings/0001193125-25-266011.md) | [19.3](/filings/0001193125-26-334174.md) | [19.3](/filings/0001193125-26-205434.md) | [20.0](/filings/0001193125-26-334174.md) |
| Total liabilities | $m | [383](/filings/0000950170-23-057805.md) | [403](/filings/0000950170-25-038427.md) | [401](/filings/0000950170-24-055159.md) | [409](/filings/0000950170-24-095821.md) | [155](/filings/0000950170-24-126018.md) | [126](/filings/0001193125-26-103276.md) | [114](/filings/0000950170-25-065173.md) | [111](/filings/0000950170-25-103611.md) | [99.8](/filings/0001193125-25-266011.md) | [94.0](/filings/0001193125-26-334174.md) | [91.1](/filings/0001193125-26-205434.md) | [67.1](/filings/0001193125-26-334174.md) |
| Long-term debt | $m | [110](/filings/0000950170-23-057805.md) | [110](/filings/0000950170-24-025464.md) | [110](/filings/0000950170-24-055159.md) | [110](/filings/0000950170-24-095821.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(15.1)](/filings/0000950170-24-126018.md) | [(44.9)](/filings/0001193125-26-103276.md) | [(59.7)](/filings/0001193125-25-266011.md) | [(87.1)](/filings/0001193125-25-266011.md) | [23.9](/filings/0001193125-25-266011.md) | [13.8](/filings/0001193125-26-334174.md) | [50.5](/filings/0001193125-26-334174.md) | [33.0](/filings/0001193125-26-334174.md) | [43.7](/filings/0001193125-25-266011.md) | [44.2](/filings/0001193125-26-334174.md) | [26.5](/filings/0001193125-26-334174.md) | [34.5](/filings/0001193125-26-334174.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(59.3) d](/filings/0000950170-24-126018.md) | [(47.5) d](/filings/0001193125-26-103276.md) | [(35.2)](/filings/0000950170-25-065173.md) | [(39.8) d](/filings/0000950170-25-103611.md) | [(34.7) d](/filings/0001193125-25-266011.md) | [(38.9) d](/filings/0001193125-26-103276.md) | [26.9](/filings/0001193125-26-205434.md) | [(13.3) d](/filings/0001193125-26-334174.md) | [2.2 d](/filings/0001193125-25-266011.md) | [(14.7) d](/filings/0001193125-26-103276.md) | [(16.4)](/filings/0001193125-26-205434.md) | [(22.4) d](/filings/0001193125-26-334174.md) |
| Capital expenditure | $m | [1.8 d](/filings/0000950170-24-126018.md) | [0.9 d](/filings/0001193125-26-103276.md) | [0.1](/filings/0000950170-25-065173.md) | [0.1 d](/filings/0000950170-25-103611.md) | [0.1 d](/filings/0001193125-25-266011.md) | [0.1 d](/filings/0001193125-26-103276.md) | [0.0](/filings/0001193125-26-205434.md) | [0.2 d](/filings/0001193125-26-334174.md) | [0.0 d](/filings/0001193125-25-266011.md) | [0.0 d](/filings/0001193125-26-103276.md) | [0.0](/filings/0001193125-26-205434.md) | [0.0 d](/filings/0001193125-26-334174.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [123](/filings/0000950170-23-057805.md) | [126](/filings/0000950170-24-055159.md) | [130](/filings/0000950170-24-095821.md) | [128](/filings/0000950170-24-126018.md) | [7.3](/filings/0000950170-25-065173.md) | [7.6](/filings/0000950170-25-103611.md) | [7.6](/filings/0001193125-25-266011.md) | [8.7](/filings/0001193125-26-205434.md) | [8.7](/filings/0001193125-26-334174.md) | [8.8](/filings/0001193125-25-266011.md) | [9.6](/filings/0001193125-26-205434.md) | [9.7](/filings/0001193125-26-334174.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 9,941,261 at 2026-08-03, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-334174.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.